How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The US AI research company Anthropic has become known for building powerful AI models while simultaneously warning about their dangers. “We are not there yet, and recursive self-improvement is not ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Caroline Banton has 6+ years of experience as a writer of business and finance articles. She also writes biographies for Story Terrace. Gordon Scott has been an active investor and technical analyst ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Investopedia / Julie Bang Holding period return/yield is the total percentage return earned from an investment ...

When someone asks me where they should invest, I always ask about their goals and time horizon. I do this to reiterate the fact that investment decisions should reflect your personal and financial ...

Recursion Pharmaceuticals recently reported mixed Q2 results, revealing a $7.67 million revenue decline and an adjusted loss of $0.25 per share. Despite these challenges, the company achieved ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...